Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance Christopher J. WebsterKelly L. GeorgeGillian R. Woollett Current Opinion Open access 18 June 2021 Pages: 379 - 387
Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy Omar SheikhToshifumi Yokota Review Article 07 June 2021 Pages: 389 - 399
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis Nan YangZeyu ChenYuling Shi Review Article 02 July 2021 Pages: 401 - 415
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) Konstantinos SyrigosIstvan AbertThe AVANA Investigators Original Research Article Open access 15 July 2021 Pages: 417 - 428
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA) Dmytro TrukhinElena Poddubskayafor the STELLA Investigators Original Research Article Open access 29 April 2021 Pages: 429 - 444
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study Shukui QinJin LiHLX04-mCRC03 Investigators Original Research Article Open access 20 May 2021 Pages: 445 - 458
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar Jocelyn CourvilleLoretta NastoupilPilar Nava-Parada Original Research Article Open access 21 June 2021 Pages: 459 - 468
Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis Stefano PiasericoAndrea ContiPaolo Gisondi Research Letter 11 May 2021 Pages: 469 - 471
